Oregon Health & Science University researchers reported that combining the BCL2 inhibitor venetoclax with CDK4/6 inhibitor palbociclib produced stronger and more durable anti‑leukemia activity than venetoclax alone in over 300 patient samples and mouse xenograft models. The team identified co‑targeting of cell‑cycle and protein synthesis pathways as a mechanism that mitigates known resistance routes to venetoclax. The study, published in Cell Reports Medicine, positions palbociclib as a candidate for combination regimens to overcome venetoclax resistance in acute myeloid leukemia (AML). Venetoclax‑based regimens have become standard for select AML patients but face universal resistance over time; this preclinical work supports rapid clinical evaluation of the combination and illustrates how repurposing approved cell‑cycle inhibitors can address resistance in hematologic malignancies.